Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 10:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 115 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Central Retinal Vein Occlusion Clear all

Conditions: Retinal Vein Occlusion
Interventions: dexamethasone implant; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Macular Edema
Interventions: Ranibizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 42
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 38 more

Conditions: Central Retinal Vein Occlusion
Interventions: Tissue Plasminogen Activator; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Macular Edema, Central Retinal Vein Occlusion
Interventions: Ozurdex, Avastin; Drug
Lead sponsor: Long Island Vitreoretinal Consultants; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 4
States / cities: Toms River, New Jersey • Great Neck, New York • Hauppauge, New York + 1 more

Conditions: Macular Edema, Retinal Vein Occlusion
Interventions: Not listed
Lead sponsor: Clearside Biomedical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Macular Edema, Retinal Vein Occlusion
Interventions: 4 mg CLS-TA, Sham, IVT aflibercept; Drug
Lead sponsor: Clearside Biomedical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 14
States / cities: Phoenix, Arizona • Beverly Hills, California • San Diego, California + 11 more

Conditions: Retinal Vein Occlusion
Interventions: Aflibercept; Drug
Lead sponsor: Tennessee Retina; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion (RVO)
Interventions: Iheezo, Lidocaine pledget; Drug
Lead sponsor: Retina Consultants of Delmarva; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Easton, Maryland

Conditions: Macula Edema, Radiation Retinopathy, Branch Retinal Vein Occlusion, Epiretinal Membrane, Central Serous Retinopathy With Pit of Optic Disc, Commotio Retinae, Vitritis
Interventions: Episcleral Celecoxib; Drug
Lead sponsor: Targeted Therapy Technologies, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Retinal Vein Occlusion
Interventions: Nicotinic acid, Prednisolone acetate; Drug
Lead sponsor: Palo Alto Medical Foundation; Other
Eligibility: Not listed
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Macular Degeneration, Retinal Vein Occlusion, Diabetic Retinopathy
Interventions: Triamcinolone Acetonide; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Ischemia, Retinal Vein Occlusion, Pathologic Processes, Retinal Diseases, Eye Diseases
Interventions: ranibizumab; Drug
Lead sponsor: David M. Brown, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Neovascular Age-related Macular Degeneration, Age-related Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion, Diabetic Macular Edema
Interventions: AngioVue SD-OCT; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Central Retinal Vein Occlusion
Interventions: Autologous Bone Marrow CD34+ Stem Cells, Sham Therapy; Biological
Lead sponsor: The Emmes Company, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Macular Edema
Interventions: ranibizumab 0.5mg, ranibizumab 1.0mg; Drug
Lead sponsor: Hanscom, Thomas, M.D.; Individual
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 4
States / cities: Huntington Beach, California • Long Beach, California • Santa Monica, California + 1 more

Conditions: Retinal Vein Occlusion
Interventions: ranibizumab, Peripheral Laser; Drug · Other
Lead sponsor: Peter A Campochiaro, MD; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 6
States / cities: Beverly Hills, California • Sacremento, California • Augusta, Georgia + 3 more

Conditions: Macular Edema
Interventions: AR-1105-CF1, AR-1105-CF2; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 11
States / cities: Phoenix, Arizona • Beverly Hills, California • Palo Alto, California + 8 more

Conditions: Macular Edema, Central Retinal Vein Occlusion, Hemiretinal Vein Occlusion
Interventions: Faricimab, Aflibercept, Sham Procedure; Drug · Procedure
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 729 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 57
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 52 more

Conditions: Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (NVAMD), BRVO - Branch Retinal Vein Occlusion
Interventions: EYE201; Drug
Lead sponsor: EyeBiotech Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 26
States / cities: Scottsdale, Arizona • Modesto, California • Mountain View, California + 21 more

Conditions: Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, BRVO - Branch Retinal Vein Occlusion, Diabetic Macular Edema
Interventions: bevacizumab; Biological
Lead sponsor: Outlook Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 3
States / cities: Springfield, Illinois • Hagerstown, Maryland • Chambersburg, Pennsylvania

Conditions: Macular Edema, Retinal Vein Occlusion
Interventions: AGN208397 intravitreal injection, dexamethasone intravitreal implant; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Macular Edema, Retinal Vein Occlusion
Interventions: KSI-301, Aflibercept, Sham Procedure; Drug · Other
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 18 Years and older
Enrollment: 568 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 81
States / cities: Phoenix, Arizona • Beverly Hills, California • Fresno, California + 75 more

Conditions: Macular Edema, Retinal Vein Occlusion
Interventions: suprachoroidal CLS-TA, suprachoroidal sham, Lucentis or Avastin; Drug
Lead sponsor: Clearside Biomedical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 72
States / cities: Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 61 more

Conditions: Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema
Interventions: FYB201 0.5 mg (0.05 mL of 10 mg/mL); Drug
Lead sponsor: Formycon AG; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 4
States / cities: Campbell, California • Long Beach, California • Hagerstown, Maryland + 1 more

Search by objective public record fields.

Ozurdex for Retinal Vein Occlusion Study (ORVO Study)

A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion

Intra-arterial Thrombolysis for Severe Recent Central Retinal Vein Occlusion

Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)

Retrospective Study of the Safety and Efficacy of Patients With RVO in Subjects Who Completed Parent Study CLS1003-201

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO

Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy

Patient Comfort Following Intravitreal Injections Using Iheezo Versus Standard Anesthesia

Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

To Study the Effectiveness and Safety of Niacin and a Topical Steroid Eye Drop to Treat Retinal Vein Occlusions

Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders

Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)

SD-OCT Angiography

Treatment of Central Retinal Vein Occlusion Using Stem Cells Study

Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab

Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion

Study Assessing AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion

A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration

A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders

Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO

Ocular Safety and Usability Study for FYB201 PFS